Amgen Bucks Trend For US Eylea Biosimilars By Avoiding Regeneron Injunction
Pavblu Biosimilar, Approved A Month Ago, Could Launch At Risk With Litigation Ongoing
Amgen has broken away from the pack of other US biosimilar challengers to Eylea in the US, by avoiding an injunction requested by originator Regeneron that would block the launch of its aflibercept rival. However, with litigation ongoing, any launch would be at risk.
